Nature Communications (Sep 2020)
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
- Hemant M. Kocher,
- Bristi Basu,
- Fieke E. M. Froeling,
- Debashis Sarker,
- Sarah Slater,
- Dominic Carlin,
- Nandita M. deSouza,
- Katja N. De Paepe,
- Michelle R. Goulart,
- Christine Hughes,
- Ahmet Imrali,
- Rhiannon Roberts,
- Maria Pawula,
- Richard Houghton,
- Cheryl Lawrence,
- Yathushan Yogeswaran,
- Kelly Mousa,
- Carike Coetzee,
- Peter Sasieni,
- Aaron Prendergast,
- David J. Propper
Affiliations
- Hemant M. Kocher
- Centre for Tumour Biology, Barts Cancer Institute—A CRUK Centre of Excellence, Queen Mary University London
- Bristi Basu
- Department of Oncology, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust—Addenbrooke’s Hospital
- Fieke E. M. Froeling
- Department of Surgery and Cancer, Imperial College London—Hammersmith Hospital
- Debashis Sarker
- School of Cancer and Pharmaceutical Sciences, King’s College London, Guy’s Hospital Campus
- Sarah Slater
- Barts and the London HPB Centre, The Royal London Hospital, Barts Health NHS Trust
- Dominic Carlin
- Division of Radiotherapy and Imaging, The Institute of Cancer Research
- Nandita M. deSouza
- Division of Radiotherapy and Imaging, The Institute of Cancer Research
- Katja N. De Paepe
- Division of Radiotherapy and Imaging, The Institute of Cancer Research
- Michelle R. Goulart
- Centre for Tumour Biology, Barts Cancer Institute—A CRUK Centre of Excellence, Queen Mary University London
- Christine Hughes
- Centre for Tumour Biology, Barts Cancer Institute—A CRUK Centre of Excellence, Queen Mary University London
- Ahmet Imrali
- Barts Pancreas Tissue Bank, Barts Cancer Institute—A CRUK Centre of Excellence, Queen Mary University London
- Rhiannon Roberts
- Barts Pancreas Tissue Bank, Barts Cancer Institute—A CRUK Centre of Excellence, Queen Mary University London
- Maria Pawula
- PK/Bioanalytics Core Facility, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way
- Richard Houghton
- PK/Bioanalytics Core Facility, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way
- Cheryl Lawrence
- Centre for Experimental Cancer Medicine, Barts Cancer Institute—A CRUK Centre of Excellence, Queen Mary University of London
- Yathushan Yogeswaran
- Centre for Experimental Cancer Medicine, Barts Cancer Institute—A CRUK Centre of Excellence, Queen Mary University of London
- Kelly Mousa
- Centre for Experimental Cancer Medicine, Barts Cancer Institute—A CRUK Centre of Excellence, Queen Mary University of London
- Carike Coetzee
- Centre for Experimental Cancer Medicine, Barts Cancer Institute—A CRUK Centre of Excellence, Queen Mary University of London
- Peter Sasieni
- Cancer Prevention Trials Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London
- Aaron Prendergast
- Centre for Experimental Cancer Medicine, Barts Cancer Institute—A CRUK Centre of Excellence, Queen Mary University of London
- David J. Propper
- Centre for Experimental Cancer Medicine, Barts Cancer Institute—A CRUK Centre of Excellence, Queen Mary University of London
- DOI
- https://doi.org/10.1038/s41467-020-18636-w
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 9
Abstract
All-trans retinoic acid - ATRA- is known to remodulate the stroma of pancreatic cancer in mice. Here, the authors carried out a Phase Ib trial in pancreatic patients and show that ATRA in combination with chemotherapy is a safe potential treatment for patients with advanced pancreatic cancer, and demonstrate a stromal modulatory effect.
